Dear Reader,

In the next few minutes, I’m going to show you how a relatively unknown piece of legislation – implemented by Donald Trump – could hand you a quick fortune.

This legislation, like putting biotechs on steroids, is set to explode the value of several select stocks as much as 110-fold. And it does this for two reasons.

First, it brings as much as $2.5 trillion pouring into the U.S. for investment.

Second, it deregulates and allows dozens of biotechs to unleash their full profitability.

Find out today exactly which stocks are set to launch from as little as $7.50 to as much as $870… and you could set yourself up for the perfect retirement.

The only thing you need to know is which stock to buy and when… which I’ll share with you shortly.

The companies we’re looking at – and the massive gains they are set to hand out – are there for the taking.

And let me assure you…

You DO NOT need to be a sophisticated investor to capture these returns.

You DO NOT need to hope and pray for any FDA approvals.

You DO NOT need to make a large investment – $500 or less will do.

You NO NOT need complex options trades.

And you DO NOT need to risk a single penny on stocks that aren’t already on a path to make billions of dollars.

If you’ve ever dreamed of hitting that one big stock that will change your life, this is your big moment.

Don’t blow it.

I can help you identify a biotech stock that will return as much as 110-times your money in the year ahead.

But, if you’re the type of person who would prefer to just invest in S&P 500 ETFs, I suggest you click away now.

You may put together a decent retirement with that mindset, but you’ll never be truly rich.

So if you’re ready for the big life-changing moment, pay attention very closely.

What you’re about to see is perhaps the easiest and most straightforward way to make a bundle on stocks.

But the opportunity will be short-lived…

Because, once Trump’s plan comes to light – and people see the amount of money flowing into biotechs – your chance will be long gone.

I believe that anyone who gets in after September 15 will have already missed at least half of the profit potential.

So you must move quickly.

After September 15, this will already be plastered on every newspaper and website across the country:

“Biotechs deliver RECORD profits… Stocks up as much as 11,000%!”

Once those gains are out the door, they won’t be available again… perhaps ever!

I want to share with you exactly which stocks to buy in the next few minutes.

There’s one in particular that is already seeing revenue explosions of 1,341%!

And you can get my free report with all the details in the next few minutes.

But first, let me show you proof why biotechs will deliver more profits over the next six months than any time in the history of the stock market.

Why Biotechs?

There are dozens of sectors likely to be affected both negatively and positively by the Trump presidency.

So what makes biotechs the perfect investment right now?

#1) You can get in at a great price.

If you wanted to buy tech stocks like Apple, Amazon, or Google… 200 shares might cost you anywhere from $30,000 to $200,000!

However, there are many biotechs – ones with substantially profitable and growing businesses – that you can get into at great prices!

You might get 100 shares for $500… and see it grow to $58,000 or more.

#2) Biotechs have delivered perhaps the biggest profits in the history of the stock market.

And it’s easy to see why.

Nearly $1 out of every $5 in the United States is spent on healthcare.

With 10,000 baby boomers retiring every day, healthcare is one of the biggest growth industries in America.

It’s a $3.2 trillion market that’s about to see even more revenue come flooding in thanks to Trump’s plans.

So, as a small company in this sector, the growth potential is unmatched.

Imagine you’re a $100 million company in the healthcare markets.

Let’s say you create a breakthrough product that reduces heart disease.

If you capture just ⅒ of 1% of the healthcare market… the value of your company grows to $3.2 billion – a 3,200% explosion.

And your shareholders get very rich.

There are dozens of examples of this happening.

In fact, in the biotech markets, it happens regularly.

Look at Aquinox Pharmaceuticals (AQXP).

It was trading for $2 on a Friday. By Monday, it hit a high of $55.75!

Investors had the chance to turn every $500 into $13,937.50!

In just two trading days!

Why?

Simply because they reported favorable test results on a drug that treats bladder pain.

That’s what’s amazing about the biotech industry.

Even the slightest good news can send a stock on an epic rise.

And when a company comes up with something truly game-changing, the gains can be even more dramatic.

Look at Intuitive Surgical (ISRG).

They built robots that helped doctors perform the most difficult and precise surgeries.

Their stock rose from $7.50… all the way to $870.33!

That’s a massive gain of 11,500%, where $500 turned into $58,022.

Look at Medivation (MDVN).

Its treatment for Alzheimer’s propelled it from just 20 cents to over $81.44!

Here, $500 turned into $203,600!

Same story with Illumina (ILMN).

It was trading as low as 88 cents. Then they created new gene-sequencing technology, and the stock climbed to a top of $219!

$500 turned into $124,431!

Questcor (QCOR) is another case.

They tackled the multiple sclerosis problem.

It was a great achievement that helped millions of people, and shareholders were rewarded for believing in their mission.

The stock zoomed up 5,000% before being acquired for $5.4 billion.

This is one of the things I love about biotechs.

They give you the chance at bigger gains than perhaps any other sector of the stock market.

But they also do it while creating products that save lives!

Look at the tech stocks with their gadgets and apps.

Even the best deliver gains that pale in comparison to biotech.

Apple is the crème-de-la-crème of tech stocks… and even they’ve only delivered 777% during the last ten years.

Medivation handed investors 40,400%… 52-times more profit!

Here’s the bottom line:

Nothing in the stock market offers bigger upside potential than biotechs. And new laws, set in place by President Trump, are about to kickstart the biggest biotech boom of all time.

Analysts are calling it “a magnificent time for investors to re-evaluate their association with this high-growth sector.”

They say that “Biotech stocks that have consistently performed well are poised to reap the maximum benefits.”

After all, $2.5 trillion is about to come pouring into the U.S. thanks to Trump’s plan.

This money is going to send biotech skyrocketing like never before.

The big moment is on September 15 when Trump is set to fully implement the de-regulation and pro-growth policies for biotech markets.

These new laws will impact biotech markets with seven powerful profit boosters.

The Profit Boosters About to
Ignite the Biotech Markets

According to a MarketWatch Analysis of what’s to come, when Trump fully implements his plan, it will…

  1. Eliminate the Government Drug Price Control Threat
  2. Create an Explosion of Biotech Buyouts, Pushing Prices Higher
  3. Create More Positive Risk-Reward Scenarios for Drug Development
  4. Allow More Collaboration Between Top Biotech Researchers
  5. Start FDA Process Reform/More Fast-Tracking
  6. Repeal the Medical Device Tax
  7. And Enact Huge Incentives for Institutional Money to Flow Into Biotechs

You absolutely must be ready.

And as these profit boosters kick in, there is one thing you absolutely need to know.

That is which biotech stands to move up 110-fold in the months ahead.

I can tell you with total confidence, we’ve found the perfect company.

The Biotech Company Most Perfectly
Positioned to Rise 110-Fold

A single company just created a new technology that will completely change the #1 most deadly disease in America.

Sadly, it kills over 800,000 people per year…

And makes life difficult for millions more.

But even more troubling… doctors say it’s almost 100% preventable.

And that’s why mountains of money are flowing into solving this huge health problem.

$316 billion is spent annually just on this single issue.

I’m talking about heart disease. It’s the #1 cause of death in America.

But one company is about to completely change that.

They’ve found a treatment method that blows everything else out of the water. It’s a way to prevent strokes and heart attacks hours before they even happen. Plus, even if a patient does experience an event, this company’s treatment can help hundreds of thousands of patients recover and live healthy lives.

Which is why it is easily my favorite biotech pick right now.

I’m going to explain why they are set up for massive profits in a moment.

Right now, you’re going to have to act quickly on this.

As you saw with Aquinox – the stock that rose from $2 to $55 in just two trading days – biotech gains can come hard and fast.

That happened because Aquinox got test results that showed it could help reduce bladder pain.

Bladder pain.

That’s all it took.

And let me tell you, that’s absolutely NOTHING compared to the truly life-altering technology this new biotech has created.

This is no “wait and see” situation with the FDA.

This company’s treatment is fully approved… already working… and delivering massive revenue growth to their bottom line of over 1,341%.

They are going to alter lives for the better, not just here in America, but all over the world.

So, let me show you just how big this will all be… and why I believe this company’s stock could multiply up to 110-fold… just like Intuitive Surgical did.

Solving the Worst Health Epidemic in
America Today

As I mentioned, the biggest killer in America is heart disease. It causes 1 in 4 deaths here.

Nearly half the population – 47% – have at least one of the risk factors.

And it’s particularly bad in the South… where heart disease is completely out of control.

The cost of this disease comes in at $316.6 billion.

But here’s what’s truly sad.

In many cases, heart disease is 100% preventable.

According to Harvard Medical School, 200,000 deaths each year from heart disease and strokes are preventable.

More than half of those preventable deaths come from people under 65.

Here’s why…

How a Heart Attack Works…

Your heart muscle needs oxygen to survive.

The blood in your system delivers that oxygen to your heart to keep it healthy.

But a heart attack occurs when the blood flow that brings oxygen to the heart muscle is severely reduced or cut off completely.

This happens because coronary arteries that supply the heart muscle with blood flow can slowly narrow from a buildup of fat, cholesterol and other substances that together are called “plaque.”

This slow process is known as atherosclerosis.

And it’s a very slow and quiet killer.

Most people under 65 don’t realize they are at risk. They have no idea this slow process is occurring…

Until plaque in a heart artery breaks and a blood clot forms.

This blood clot can block the blood flow through the heart muscle.

And that causes a heart attack or myocardial infarction.

About every 40 seconds, someone in the United States has a myocardial infarction.

That’s why heart disease is such a costly and devastating disease.

It’s happening all over the country, literally every minute of the day. But here’s the thing…

The company I’m telling you about today has a solution.

They’ve created a new cardiac imaging technology that can alert doctors long in advance of a heart attack that something isn’t right.

From there, they can do something about it.

The company has a proven, approved way to prevent heart attacks and strokes from killing people.

According to the experts, their technology is “turning sci-fi into reality.”

It’s been called the “gold standard” and over 1 million patients are now using it.

That’s just the tip of the iceberg.

Analysts are estimating over 40 million people could soon use their treatment. And that’s just here in the United States.

It’s the reason I believe their stock is about to soar like nothing we’ve seen in the biotech sector before.

I believe you should invest in this company now… not just because it’s likely to make you very wealthy.

But because you’ll also be a part of one of the greatest life-saving efforts in the history of mankind.

Let me give you a few facts about the company that show you just how big this is all going to get.

How this Single Company Will Save Hundreds of Thousands of Lives…
And Reward Its Shareholders with a
Massive Payday in the Process

The company is based in the Northeast of the United States, and they have three separate revenue streams.

The first focuses on diagnosing and preventing heart rhythm disorders.

The second generates cash by selling their cardiac imaging technology to pharmaceutical companies.

And the third is through equipment sales to hospitals and healthcare providers.

The company has massive profit margins… and generates a mammoth 49% return on equity.

So here’s why all of that is important…

The number of patients using this technology is shooting through the roof. It’s over a million and growing at a historic rate.

That’s why revenue is leaping up by 1,341%!

Consider… between 2006 and 2010, some of Apple’s very best years, revenue grew by just 228% total!

This company is growing 6x faster in just one quarter!

If you hesitate even for a moment, you risk missing out on the explosion in value that’s coming in the days ahead.

And with biotechs, the gains that come from identifying a top performer early are out of this world.

Biotechs Like This Don’t Come Along
Every Day… But When They Do, the
Gains are Life-Altering

Gilead Sciences (GILD) is a great example.

They set out to tackle a really tough disease – HIV. At the time, it was an epidemic that was out of control.

But, when they came out with an antiviral treatment that worked, it was a true game-changer.

They saved and extended millions of lives and, of course, the company became much more valuable.

 When they started, the company was tiny… trading for just 70 cents per share.

But as their drugs spread from hospital to hospital around the globe… it kept rising.

After many years, the stock maxed out at $119 per share – 170 times higher than where they first started.

$500 in Gilead turned into $85,000!

I love stories like this.

It’s great to put money into a company to help them grow… so they can save lives AND reward shareholders.

The company I’m telling you about today is on the very same path.

I expect them to increase in value anywhere from 2,000% to 11,500% as we saw with Intuitive Surgical.

In fact, history shows it could be even more.

Take Celgene (CELG), for example…

This company was completely off most people’s radar…

They were trading for pennies on the dollar at just 60 cents.

Then, they created revolutionary blockbuster drugs to fight tumor growth.

And here’s what happened to the stock:

It started climbing and didn’t stop until it hit a peak of $134.90.

Its ascent measured in at 22,383%, where every $500 turned into $112,416!

Every year, there are huge biotech gains.

Even in 2016, when the threat of a Hillary Clinton presidency depressed the market, we saw record gains in companies like…

That means…

Every $500 you put into a company like Axim Biotechnologies… turned into $10,000.

That’s a trade I’ll make every single time.

Put $10,000 into a trade like that and you end up with $200,000!

All you need to do is identify when a big move in biotech is beginning – which is happening now due to Trump’s new legislation – and then find the stock likely to have the biggest headline-generating medical treatment.

And that’s the company that has the chance to save 200,000 people or more from heart disease.

Of course, nothing in life is ever certain. But if there is a company in the health care industry I’d bet on rewarding shareholders…

It would be the company tackling a disease that’s both widespread, but also very preventable.

Think about it…

With diseases like Cancer or Alzheimer’s, the best we’re doing is trying to slow them down.

With heart disease, we know it’s a solvable problem. It’s just a matter of finding the right treatment.

This company has it.

But, to really do well when this takes over the market, you need to be in before September 15.

Why such a hard deadline?

Trump’s Legislation Will Send
Biotechs Soaring…

I’ve shown you a number of huge gains for small biotechs in today’s presentation.

You’ve seen the 11,500% gain in Intuitive Surgical…

The 2,687% gain in Aquinox Pharmaceuticals.

The 40,400% gain in Medivation.

Every one of these companies started the same way.

Doctors and scientists received funding from venture capitalists or other investors.

They used that capital to do research and create life-saving products.

Then, they sell those products to recoup the billions of dollars it cost to do that research… and they use the proceeds to reward the investors who took the risk of funding the research in the first place.

But, during the Obama years, that all changed.

Over-regulation stopped many biotechs from forming. It just became too costly.

As Representative Jim Greenwood out of Pennsylvania writes, regulations are killing small life sciences companies and the patients they might have otherwise saved.”

Over a five year period, only 55 new biotechs were founded… an unbelievably low number.

But now… that’s changing very quickly.

New legislation – already passed by Congress and now being implemented by Trump – is opening up the biotech markets like never before.

We’re seeing 212 new biotech IPOs.

Two regulations are being cut for every one that’s added.

And new incentives are creating an unprecedented situation where tiny biotech stocks are about to shoot through the roof.

In a Forbes interview, Marketocracy’s top biotech fund manager said “biotechs are set up for an extraordinary comeback.”

And Fortune reports that “Donald Trump’s presidency could unleash a Pharma merger boom.”

That’s because the big pharma companies recognize that they better buy up all these cheap biotechs now before they soar in value.

And that could happen very soon.

The prestigious organization Portfolio Wealth Global just alerted its clients that there are “massive gains ahead” in biotech.

Because, if you find just one great biotech each year… it can be enough to fully fund your entire retirement on just $500.

Let me show you…

The $500 Fully-Funded
Retirement Guide

To show you just how potentially life-changing the biotech market can be… let me walk you through what can happen with $500 and just one biotech trade each year.

I don’t believe any other sector of the economy can deliver bigger gains.

In fact, just pinpointing one big breakout biotech each year can make you more money than 50 years of regular investing.

All of these examples are real. This isn’t hypothetical… but rather a documented set of trades between 2014 and 2016 that could have made you rich.

Let’s start with step #1.

2014: Buy Axim Biotechnologies
Turn $500 Into $20,000

Axim Biotechnologies is a U.S. based company founded just a few years ago.

They specialize in treatments for Parkinson’s, Dementia, Multiple Sclerosis, and Crone’s Disease.

In 2014, it was not a well-known company, and it was very cheap. Shares traded for just 25 cents.

That’s a price anyone can afford.

So $500 would have gotten you 2,000 shares.

Six months later, those same shares were trading for $10, so you would have been sitting on $20,000!

In total, that’s a 3,900% gain in one year.

And 2015 was about to hand you another massive opportunity…

2015: Buy Aquinox Pharmaceuticals
Turn $20,000 Into $557,500

This trade shows you just how fast biotechs can blow up your account to massive levels.

You’re coming off your first win… and with your second win, the gains are going to grow exceptionally fast.

In 2015, Aquinox Pharmaceuticals was trading for just $2, as we covered earlier.

Your $20,000 in biotech winnings from 2014 got you exactly 10,000 shares.

In just a matter of days, your shares launched to $55.75.

Your 10,000 shares were suddenly worth $557,500!

You’re now sitting on half a million on just two trades.

That’s the power of identifying just one big biotech winner each year.

And in 2016, you could have taken it even further…

2016: Buy Corbus Pharmaceuticals
$500,000 Turns Into $4.41 Million

It’s amazing to think just three moves could make you a multi-millionaire.

But let’s say after you did so well in 2014 and 2015… you wanted to try to find just one more biotech winner.

But you didn’t want to risk it all.

So you take $57,500 out of your winnings.

That means you’re guaranteed to keep over 1,000X your initial $500 investment.

You put the remaining $500k into the Massachusetts Pharmaceutical company, Corbus Pharmaceuticals.

In January 2016, Corbus was trading for just $1.11 but, by October, it went all the way up to $9.79.

Your $500,000 would have grown to $4.41 million!

It’s pretty shocking how just a few smart bets could multiply your money that fast… but it is possible if you’re able to identify the top biotechs each year.

And remember, the three stocks I just showed you were solving problems like Parkinson’s, Multiple Sclerosis, and bladder issues.

While they’re all worthy causes… none of them compare to how life-changing a treatment for heart disease could be.

That’s why I believe the company I’ve shared with you today will be the #1 biotech performer in the next 12 months.

It could go up as much as 110-fold… just like Intuitive Surgical did when it launched from $7.50 all the way to $870.

With Trump’s de-regulation plans about to hit… a tsunami of cash is about to flow into the biotech sector.

And you better believe the big money will bet on the company with a breakthrough heart disease treatment.

The profit opportunity is simply staggering.

“Stay long” said one analyst to MarketWatch, as the biotech industry gets new support from government.

“I feel like a rejuvenated man,” says RBC Capital Markets biotech analyst Michael Yee. “Once again, people are coming back to talk about biotech. We are back in gear.”

 “Money is Flowing Into Biotech Again”
—Boston Globe Media’s Stat News

With the markets coming to the tail end of a bull run, this opportunity might be your last chance at big gains for years.

How could a 110-fold return now change your life?

Could you pay off the mortgage and live a freer lifestyle?

Could you take the family on more trips together?

Perhaps you’d like to upgrade your home or do a kitchen renovation?

Finding that one great biotech stock can do that for you.

We’ve seen more big winners here than in perhaps any other industry.

But after these big changes on September 15, the fastest profits will be gone.

Let me share with you how to get in on the best biotech stock for the next 12 months.

A $3 Trillion Industry that’s About to
Enter Its Most Profitable Era Ever

Before I tell you how to score your first profits… I should introduce myself.

My name is Roger Michalski.

I’m the publisher at Eagle Financial Publications.

At Eagle, we have a firm belief in free markets, personal liberty, and the right of every person in America to thrive financially.

Our publications are read by hundreds of thousands of people each week.

And much of it is thanks to our incredible team of knowledgeable and experienced financial analysts.

Dr. Mark Skousen, PhD Economist, our longest-tenured investment strategist follows a simple philosophy.

He looks for global shifts in cash flows to locate the next bull markets.

And then Dr. Skousen identifies the few opportunities set to generate the highest profits.

Right now, Dr. Skousen believes biotech stocks offer some of the biggest profit potential… and the company with the heart disease breakthrough could be the biggest winner of all.

Let me assure you, Dr. Skousen has a long history of calling exactly what will happen in the markets.

In 1987, six weeks before the October 1987 crash, Dr. Skousen warned his subscribers to “get out of stocks now.” He was one of the only investment advisers to anticipate the crash.

In October, 1989, he startled subscribers and investors at an Orlando investment conference by predicting, “The Berlin Wall will be torn down!”  One month later, on November 9, it was – igniting a period of massive global growth after the end of Communism.

In January 1995, Skousen predicted that, “The Nasdaq will double and then double again.” The Nasdaq was at 750 at the time and closed the decade over 3,000.

But in 2000, Skousen then warned investors of an impending bubble in internet stocks, based on his unique “Austrian” theory of the business cycle.

Soon after, the Nasdaq collapsed.

At the bottom of the markets in 2009, he predicted that the Dow would hit 10,000 by the end of 2009, a very unpopular opinion at the time.

He told his subscribers that stocks were a “screaming buy.” And, once again, he proved to be right.

Then, in 2012, Dr. Skousen called for a major pullback in gold. Readers who listened to him avoided the 30-40% drop.

It’s an impressive set of uncanny market calls if you ask me.

Due to his impressive macroeconomic analysis, Dr. Skousen has seen hundreds of big wins over the years.

But he tells me that the coming biotech explosion – and the profits it will generate – are an unprecedented wealth-building event.

We’re talking about an entire industry entering an extended boom period.

And creating massive winners for a small group of top stocks.

If you’re missing this situation by holding cash… or simply investing in broad market ETFs… you could be costing yourself hundreds of thousands in retirement dollars!

Because when Dr. Skousen’s system says it’s time to buy… you absolutely must pay attention.

Dr. Skousen’s System for
Identifying Huge Biotech Gains…

When it comes to stock investing… a lot of people get wrapped up in the story.

If they hear a good story, they want to invest.

But a story is just that. It doesn’t give you the full truth.

That’s why Dr. Skousen puts every stock he recommends through a rigorous set of proven tests that hand him the biggest winners.

Only a few companies each year match his criteria.

Out of the 4,000 or so publicly traded stocks, it might just be three biotechs that he feels have big-time potential.

But those three stocks can completely transform your portfolio.

You’ve already seen how just one big winner in biotech each year could help you become a multi-millionaire.

It just comes down to picking the best ones.

Here are a few of the crucial things Dr. Skousen looks for…

Biotech Factor #1: Must Address a Major Disease.
If a company has a breakthrough treatment for a rare disease that affects 10 people worldwide… it’s not going to be a moneymaker… plain and simple.

But when you’re solving a major problem like heart disease – the #1 killer in the U.S. – then that’s a huge deal! And it’s likely to send the stock soaring.

Biotech Factor #2: Must Have Extremely Positive Testing or an Approved Product.
FDA approvals can be great for a stock… but they are very difficult to predict.

That’s why Dr. Skousen only likes to target companies with overwhelmingly positive results, where an FDA approval is virtually assured.

Or, better yet, in the case of today’s opportunity, a company that already has full approval!

Biotech Factor #3: Must Have Strong Financial Metrics.
You don’t want to invest in companies that are burning cash.

While some eventually pull out of it, your risk level is greatly increased if the company is losing money quarter after quarter.

The company Dr. Skousen is recommending now has huge profit margins. Revenue is up 1,341%. Return on Equity is a mammoth 49%.

Customers are growing at a historic rate.

That’s what you want.

Biotech Factor #4: Must Have a Wide Array of Products.
If a biotech is going to succeed long-term… it can’t do so on just one drug or treatment.

That’s why today’s company is another perfect candidate.

It has three separate revenue streams when it comes to heart disease.

But it’s also created a new treatment for Diabetes that we haven’t even mentioned yet.

Diabetes is a growing epidemic in America… and they have the chance to help millions of patients across the country.

That sort of diversity will keep the company’s financials humming for many years.

Biotech Factor #5: Must Have an Urgent Catalyst.
A big catalyst can have a major impact on individual stocks or the sector as a whole.

And the coming implementation of Trump’s plans on September 15 could create a massive boom period for biotechs.

As analysts report, the legislation is set to…

  1. Eliminate the Government Drug Price Control Threat
  2. Create an Explosion of Biotech Buyouts, Pushing Prices Higher
  3. Create More Positive Risk-Reward Scenarios for Drug Development
  4. Allow More Collaboration Between Top Biotech Researchers
  5. Start FDA Process Reform/More Fast-Tracking
  6. Repeal the Medical Device Tax
  7. And Enact Huge Incentives for Institutional Money to Flow Into Biotechs

Imagine getting in on this single company today.

It has every element you look for in a major biotech win.

Plus, new government laws are coming in like rocket boosters to take it to the next level.

As the analysts at Portfolio Wealth Global say: “Donald Trump’s presidency is a real nitro boost for the future of the biotech sector in the U.S.”

The Time to Move is Now!

It’s important to note: The time to move is now.

Once a sector gets hot – and CNBC starts talking about it day after day – it’s too late.

You need to move now when prices are cheap and the profit potential is the highest.

Biotechs in this sort of position have delivered explosive gains:

If you act now as the next run of biotech begins, you could end up multiplying your money as much as 110-fold.

Heck, Medivation handed investors 404-times their money!

It’s happened many times before.

So why not give yourself the chance to land one of these massive winners today.

You absolutely should look at the company Dr. Skousen has identified.

Its heart disease treatment is the type that can propel companies to untold heights.

But let me tell you one thing you should NOT do.

Don’t Go Out and Buy
Every Cheap Biotech You See…

Dr. Skousen believes there’s going to be a major boom in biotech stocks.

But, as with anything else, there will be winners and losers.

When it comes to truly making money, targeting only the most profitable opportunities is vital.

There are 165 biotech stocks trading on the Nasdaq alone.

Dr. Skousen and his research team have run them all through his targeting system to identify the best stocks with very high probability of shooting up.

After running them through his system, only three matched all the criteria he looks for.

These three have the potential to go up over 1,000%.

If everything plays out right, they could be some of those massive winners that deliver 110-fold gains.

As you’ve seen, just finding two to three big biotech winners can turn $500 into over $4.4 million.

The first you need to own today is the company with the treatment for heart disease.

Dr. Skousen has written up a full report on the company.

In it, he digs into the financials… how the treatment works… how many patients they could reach… the size of their market… and where he expects the stock to go.

The special report is called: The Company that Will Put an End to America’s #1 Cause of Death.

He’s made that report available for download today – free of charge.

You can download your copy right after this presentation. Open it and see exactly how to lock in the biggest profits before the September 15 catalyst.

But that’s not all…

You’ll also receive access to reports on each of Dr. Skousen’s other two favorite biotech stocks.

All for free.

Report #2: Tackling Central Nervous System Diseases

No doubt you’ve encountered someone who suffers from a central nervous system disorder.

There are neurodegenerative disorders like Alzheimer’s and Parkinson’s…

Then there are CNS disorders like multiple sclerosis, epilepsy and meningitis.

These are major debilitating diseases that affect hundreds of thousands of Americans.

But one company is doing something to stop it.

Their focus is to create drugs that treat the most debilitating of diseases that affect the spinal cord and brain function.

The company has two treatments – already approved – generating over $250 million in annual revenue.

But that number could be on the verge of growing tremendously.

They have three more drugs in the late stages of approval. Two of them are estimated to have “a market potential exceeding $3 billion per year.”

Imagine for a minute what that increase of revenue will do.

Go from $250 million to $3 billion per year… and you’re talking about the company growing at least 12 times in size.

It’s no wonder the stock recently jumped 12% in a single month.

But that’s just an opening move.

Once September 15 hits, expect the big institutional money to hit. And the stock to go parabolic.

That’s why I’d like to send you Dr. Skousen’s second biotech report: The Next $3 Billion Per Year Pharmaceutical Company.

He’s taken the company through his rigorous analysis, and found that it matched every one of the criteria he’s looking for.

It could be another massive 1,000% winner… perhaps bigger.

And you can receive a copy now to download – completely free.

And there’s more…

Report #3: Finally a Company That Lowers Healthcare Costs

One of the big controversies of today is the massive increase in healthcare costs over the last eight years.

Premiums are expected to spike another 25% in 2017. It’s driving some families to the poorhouse.

Take Irene Solesky of Maryland.

She has to pay $1,351 per month for a bronze plan! And her deductible is $13,000!

Here’s what she told CNN:

“It’s a catastrophic policy as far as I’m concerned,” said Solesky, 55, noting her Obamacare policy costs twice as much as her mortgage. “Medical insurance was meant to keep medical expenses from driving you in financial ruin, not for the medical insurance to drive you in financial ruin.”

Enter a new company whose mission statement is to “reduce the cost of care” by creating non-invasive approaches to healthcare issues.

The company has won awards for its innovations in patient safety, newborn care, diagnosing respiratory problems, medical design, best new health product, and tech innovation.

They’ve done it with products that address brain ailments, solve respiratory problems, and non-invasive blood pressure treatments.

As a result, the company has grown its revenue by 171%.

Essentially, what the company is doing is finding far less expensive ways to solve problems than the major surgeries, and expensive and invasive treatments that so many hospitals seem to recommend.

They’re now operating in 21 countries.

And their reach should only grow from here.

As their CEO says, “I hope we can continue rewarding our employees, customers, and shareholders through our long view on humanity and the advancement of medicine.”

It’s a feel good company… with major profit potential.

All the details are in Dr. Skousen’s new report: The #1 Company Solving the Healthcare Cost Crisis.

I’ll send you each of these three biotech reports… completely free.

Get Free Access to Each of
Dr. Skousen’s New Biotech Reports

But one thing I should make clear…

Dr. Skousen doesn’t only focus on biotech stocks.

It just so happens that the biggest profits in the months ahead are going to come out of that sector.

It’s a rare chance to collect up to 110-times your money thanks to the stocks I’ve outlined in this presentation.

Going forward, there will be more opportunities to profit, whether in energy, new technologies, financial stocks, or private investing.

With Dr. Skousen at the wheel, he’ll guide you through every major shift in the economic landscape and into the very best performing stocks.

As he likes to say, “there’s always a bull market somewhere.”

And if you can identify it, you’ll have the chance to increase your wealth very quickly.

That’s why I want to set you up with a risk-free trial of Dr. Skousen’s personal newsletter publication, Forecasts & Strategies.

He’s been the editor for 37+ years… not once missing a deadline along the way.

It’s as impressive a run as anyone has had in the financial publishing industry.

I’ve seen hundreds of so-called experts come and go over the years, but Dr. Skousen’s outlasted them all.

And I can tell you why…

It’s because he delivers the goods, plain and simple.

By subscribing today, you’ll join Dr. Skousen’s group of wealth builders that have proven to make more money… and collect more consistent winners… than just about any group in the investing world.

For example, we have a subscriber named Jared K. This gentleman has tried over 20 newsletters, going from one to the next searching for something that actually worked… Until he found Forecasts & Strategies.

Now, Jared never has to subscribe to another newsletter again:

“Mark Skousen has been the only one to consistently make me money in the 7 years I subscribed to Forecasts & Strategies. He’s the best!”

Joshua J. has had a similar experience. Here’s what he told Dr. Skousen:

“Forecasts & Strategies has made me a good deal of money in the last couple of years. No other financial guru seems to have your ability to separate the chaff from the grain. Your newsletter is the greatest!”

Dr. Skousen uses his long-term experience, and the wealth-building secrets he’s amassed – like the one I’ve shared with you today – to help people see returns unlike anything they can receive from traditional stock brokers and money managers.

Take Ron M. In his first 10 months as a subscriber, he invested $48,260 following Dr. Skousen’s recommendations.

“So far I have received $7,156 in dividends and have a capital gain of $22,180.”

The impact Dr. Skousen has had on people’s lives is amazing.

And I believe you’ll see the same results with Forecasts & Strategies.

Each issue consists of…

You’ll receive all of this as part of your risk-free trial.

Plus, you’ll get each of his three biotech reports… all FREE as bonuses for signing up today.

On top of that, you’ll also get access to each of Dr. Skousen’s wealth-building bonuses…

Special Wealth-Building Report #1: Dr. Skousen’s Five Favorite High Income Investments

As I mentioned before, Dr. Skousen is a very good stock picker. He’s consistently finished as a top performer in a contest held each year by Stock Advisors’ editor, Stephen Halprin. (I’ll show you in a moment what Halprin had to say about Dr. Skousen’s performance.)

But first, I want to put another report in your hands. In it, Dr. Skousen reveals his five favorite companies that generate both huge income and very fast growth potential. The moment you agree to become a new Forecasts & Strategies subscriber today, I’ll have it sent to you right away.

Special Wealth-Building Report #2: Forecasts & Strategies Quick Start Guide

Dr. Skousen put together this special report to help you make the most out of your subscription. Once you’ve gone through the six easy steps for maximizing your Forecasts & Strategies subscription, you’ll be able to hit the ground running.

With this how-to guide for using the service, we make everything as effortless and rewarding as possible for you.

Plus, you’ll get…

One More Special Bonus: Access to Dr. Skousen’s Personal Hotline

Throughout the year, Dr. Skousen will send you personal voice messages telling you what to expect in the week ahead.

If anything big is happening with the Fed, new legislation, global economic markets, or the biotech industry, you’ll know exactly how to play it for maximum profits.

The hotline will also include updates on current positions, news on earnings reports or big announcements from our recommended stocks.

And, of course, if it’s time to take profits, you’ll get details on exactly how to handle that.

In short, you’ll have everything you need:

Instructions on which stocks to buy, and when…

Alerts telling you when it’s time to sell…

Details on the profits you’ll collect.

The hotline is Dr. Skousen’s way of always keeping in touch, so you never feel like you’re doing this by yourself.

And you’ll get everything I’ve promised above simply by taking a risk-free trial of Forecasts & Strategies.

Perhaps the Best Deal
We’ve Ever Offered…

Now, normally, a package like this would run somewhere in the $500 or $600 range.

Just a single subscription alone to Forecasts & Strategies normally costs $249 per year.

However, we know that you have a lot of options out there. And we want the opportunity to build a relationship with you, so you can understand the value of Dr. Skousen’s work.

That’s why we’re offering this full package for just $49.95 today.

That’s only 13.5 cents a day.

It’s a steal for everything you’ll get…

But, you may be wondering, why only 13.5 cents a day? Isn’t that ridiculously cheap to get direct insight from one of the Top 20 Living Economists?

The simply answer is…

Yes!

At $49.95, we actually lose money by bringing on new subscribers.

It’s a big risk on our end.

But we do it for one reason.

We know that Dr. Skousen has a long storied career of making people money.

Consider this…

Stephen Halprin, editor of Stock Advisors, runs a contest each year between all the leading newsletter publishers. Everyone submits a pick at the beginning of the year… And then Stephen gives out awards at the end of the year.

Here’s what Halprin had to say about Dr. Skousen…

“For over 25 years, I have conducted an annual feature asking the nation’s leading newsletter advisors to select their favorite stock for the coming year. Year after year, Mark has consistently been among the top performers in this contest. Indeed, out of some 100 financial advisors, Mark has ranked in the top few spots more than any other.”

We know that if you give Dr. Skousen’s research a chance… you’ll do extremely well.

We give you access to his work at a major discount, so we have a chance to prove its full value to you.

We know that we have to do right by you, because if we don’t, our business will fail.

It’s that simple.

We are willing to bet the business on Dr. Skousen, because he’s been publishing Forecasts & Strategies for 37+ years!

He’s lasted longer than virtually every other stock picker on the planet… and only because he is a true master at his craft.

In fact, we’re so confident in his work, we’re willing to add one more big reason to take us up on our offer today.

Take the Next 90 Days to Put Us
Through the Ultimate Test

Go ahead and subscribe to Forecasts & Strategies today…

If at any time you are dissatisfied in any way, you can get 100% of your money back…

And still keep everything we’ve given you.

All the risk is on our shoulders!

And remember, Dr. Skousen’s premiere biotech recommendation today has the chance to deliver profits up to 110-fold in the coming months.

$500 could turn into $58,000… giving you the chance to go on a world cruise, pay off a huge chunk of your mortgage, buy a new car, or perhaps just put it toward a better retirement.

All of that is possible.

And your chance comes with a simple zero-risk decision to give Forecasts & Strategies a try.

There really is no better sector than biotech in delivering massive wins over 10,000%.

It’s happened with surgical robots, HIV drugs, and even something as simple as positive test results for a bladder pain treatment.

So you can only imagine how big the gains will be on a company that can eliminate over 200,000 deaths from heart disease.

Investors in this company are set up to see record profits on an unmatched scale.

Thinking about the size of that opportunity, I can’t see any reason to let this opportunity pass you by.

YOUR Action to Take

If you’re ready to take total control of your financial future, I urge you to subscribe to Dr. Skousen’s Forecasts & Strategies today.

Simply click the button below to get started with your 12-month risk-free trial.

Or, for an even better deal, opt for our 2-year subscription. When you do, you’ll get 24 full months of Forecasts & Strategies, and an even bigger discount off of the regular price.

Subscribing for two years is only $89.

That’s an 82% discount from what we normally charge, and a savings of $409! 

Plus, 2-year subscribers will get these 2 special investments reports – also FREE of charge. 

2-Year Bonus Report #1: How to Profit from Rising Interest Rates

Dr. Skousen put together this special report to help you make the most out of your subscription, even in a rising interest rate environment. In it, you’ll find the investments that typically work best when interest rates go up… along with strategies to further protect your portfolio in this environment.

2-Year Bonus Report #2: Lucrative Loopholes: 4 Ways to Keep More of Your Money Out of the Taxman’s Reach

Even if President Trump lowers taxes as promised, investors like you and me may still be on the hook to the government for a big chunk of change. That’s why it’s more important than ever to make sure you keep the wealth you’ve earned. This special report tells you how to do exactly that.

Now, whether you subscribe for one year or two, you’ll still be covered by our 90-day, no-risk 100% satisfaction guarantee.

So what are you waiting for? Click the button below now to get started.

It will take you to a secure order form where you can review everything before making your final decision.

If you have any remaining doubts… let me leave you with this.

It’s the words of one of Dr. Skousen’s subscribers, Steve, after he QUIT Forecasts & Strategies.

“I let my subscription to Forecasts & Strategies lapse, and regretted my decision. Looking back, I saw that a lot of your calls were right on the money. After a year’s absence, I recently re-subscribed.”

I don’t want you to look back and regret missing the massive boom coming in biotech.

Sure, you could subscribe later. But the biggest profits will be gone.

Remember, all the risk is on our shoulders.

Simply click the button below now to get started…

Sincerely,

Roger Michalski
Publisher, Eagle Financial Publications

P.S. With $316.6 billion headed toward the heart disease market, we expect Dr. Skousen’s biotech to have the chance to jump up to 110-fold.

Remember, Aquinox Pharmaceuticals leapt from $2 to $55 in just two trading days. And that was simply from some positive test results on a bladder pain treatment.

The heart treatment Dr. Skousen’s recommendation has put together is so much bigger… It could save 200,000 lives or more… and reward shareholders mightily in the process.

It feels great to invest in companies that truly make a difference.

So, I urge you, very strongly, to click the button below now to get started.